A clinical trial has found that treatment with the immunomodulator interferon beta-1a plus the antiviral remdesivir was not superior to treatment with remdesivir alone in hospitalized adults with ...
Patients with clinically isolated syndromes (CIS) are prone to develop multiple sclerosis (MS). The randomized, placebo-controlled CHAMPS trial found early treatment with interferon -1a to be ...
Both interferon-beta (IFN-beta) and glatiramer acetate have been established as effective disease-modifying agents for the treatment of patients with multiple sclerosis (MS). Both of these medications ...
Specialists in neuroimaging at UB have proposed a mechanism by which interferon beta-1a may limit brain atrophy in multiple sclerosis (MS) patients. The positive effect of interferon beta-1a, a ...
A clinical trial has found that treatment with the immunomodulator interferon beta-1a plus the antiviral remdesivir was not superior to treatment with remdesivir alone in hospitalized adults with ...
SAN FRANCISCO -- A company hoping to market an inhalable formulation of interferon beta for viral lung diseases isn't dissuaded by phase III trial results in 623 hospitalized COVID-19 patients, which ...
A study published in this week’s issue of THE LANCET suggests that high-dose interferon beta-1b administered every other day is more effective than interferon beta-1a once a week for people with ...
A clinical trial has found that treatment with the immunomodulator interferon beta-1a plus the antiviral remdesivir was not superior to treatment with remdesivir alone in hospitalized adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results